Quoted text
According to the Financial Times, QuidelOrtho, a joint venture between diagnostics company Quidel Corporation and Ortho Clinical Diagnostics, is exploring a sale of its testing unit as private equity (PE) firms intensify their focus on healthcare companies. The move comes amid broader consolidation in the diagnostics sector, where valuations have surged following the COVID-19 pandemic.
QuidelOrtho’s potential sale marks a shift in strategy for the diagnostics industry, where private equity firms have increasingly targeted companies with strong cash flows and growth potential. The Financial Times reported that the testing unit, which includes rapid antigen and molecular testing platforms, could fetch a valuation exceeding $5 billion, reflecting the sector’s elevated multiples. This follows a wave of acquisitions in diagnostics, including Thermo Fisher Scientific’s $12.6 billion purchase of bioMérieux in 2023 and Roche’s $4.3 billion acquisition of T2 Biosystems in 2022.
The sale process, which is in early stages, has drawn interest from at least three PE firms, according to people familiar with the matter. QuidelOrtho’s parent companies, Quidel Corporation and Ortho Clinical Diagnostics (owned by Thermo Fisher), have not confirmed the discussions but have acknowledged internal evaluations of strategic options. Analysts cite the unit’s dominance in point-of-care testing—particularly in infectious diseases—as a key driver of its appeal.
For the entertainment and media industries, the implications extend beyond diagnostics. QuidelOrtho’s testing platforms have been critical in large-scale events, including music festivals and sports tournaments, where rapid results are required to manage crowds. For instance, the unit’s rapid antigen tests were deployed at Coachella in 2022 and the Super Bowl in 2023, ensuring compliance with health protocols. A sale could disrupt supply chains for these events, potentially leading to higher costs or delays in securing testing solutions.
The timing of the potential sale is notable. Private equity activity in healthcare has accelerated in 2026, with firms deploying record capital into diagnostics, medical devices, and digital health. According to PitchBook, PE investments in healthcare reached $112 billion in the first half of 2026, up 28% from the same period in 2025. This surge reflects a broader trend: the diagnostics sector’s resilience post-pandemic, with companies benefiting from sustained demand for infectious disease testing and emerging applications in oncology and cardiology.
What happens next for QuidelOrtho’s testing unit?
The sale process is expected to take six to nine months, with due diligence focusing on the unit’s revenue growth and margins. QuidelOrtho reported $2.1 billion in revenue for 2025, with the testing division contributing roughly 40% of that total. Potential buyers will scrutinize the unit’s ability to maintain market share amid competition from Siemens Healthineers and Abbott Laboratories, both of which have expanded their point-of-care portfolios in recent years.
Industry observers suggest the sale could reshape the diagnostics landscape. “This is a rare opportunity to acquire a fully integrated testing platform with global reach,” said one healthcare analyst, noting that the unit’s pipeline of new assays—including a rapid test for respiratory syncytial virus (RSV)—adds long-term value. However, integration risks remain, particularly if the buyer lacks experience in QuidelOrtho’s core markets, such as emerging economies where the company has strong distribution.
For event organizers, the uncertainty could prompt early contracts with alternative suppliers. “We’re already in talks with three vendors to lock in testing for next year’s festival season,” said a spokesperson for Goldenvoice, the company behind Coachella. The spokesperson declined to name the vendors but confirmed that cost and reliability are top priorities.
The Financial Times reported that Quidel Corporation and Thermo Fisher have not set a deadline for a decision, but sources indicate pressure from shareholders to explore options. Quidel’s stock has underperformed peers in 2026, with analysts citing the need for a transformative transaction to unlock value. Thermo Fisher, meanwhile, has signaled openness to divesting non-core assets, though it has not explicitly linked QuidelOrtho to that strategy.
Why does this matter for the entertainment industry?
The diagnostics sector’s consolidation has direct implications for live entertainment, where health and safety protocols remain non-negotiable. QuidelOrtho’s testing platforms have been a cornerstone of event operations, particularly in high-density gatherings like music festivals, concerts, and sports. A sale could lead to:
Item
Higher testing costs if the new owner prioritizes profitability over accessibility.
Supply chain disruptions if the transition period extends beyond six months.
Potential delays in deploying new assays, such as those for emerging pathogens, which could impact event planning.
The Financial Times noted that private equity buyers often streamline operations to improve margins, which could result in reduced testing capacity or higher prices for event organizers. “We’ve seen this play out before—when PE firms acquire diagnostics companies, the first thing they do is cut R&D and focus on cost efficiency,” said a former executive at a rival testing firm. “For events, that means fewer options and higher expenses.”
The entertainment industry’s reliance on diagnostics was underscored during the pandemic, when rapid testing became essential for touring bands and film productions. For example, Taylor Swift’s 2023 Eras Tour required on-site testing for all crew members and performers, a model that could become more expensive if QuidelOrtho’s pricing increases post-sale. Industry insiders suggest that organizers may need to diversify their testing partners to mitigate risks.
How does this compare to past diagnostics acquisitions?
The potential sale of QuidelOrtho’s testing unit aligns with a pattern of PE-driven consolidation in healthcare. Since 2020, at least 12 diagnostics companies have been acquired by private equity firms, with valuations averaging $3.8 billion per deal, according to data from Dealogic. Key transactions include:
Item
Karius’s $1.8 billion acquisition by Roche in 2022 (focused on liquid biopsy).
BioFire’s $1.3 billion sale to Thermo Fisher in 2021 (molecular diagnostics).
Cepheid’s $8.6 billion buyout by PE firm KKR in 2020 (point-of-care testing).
Unlike these deals, QuidelOrtho’s testing unit combines rapid antigen and molecular testing, creating a more comprehensive offering. This dual capability has made it a target for buyers seeking to dominate both at-home and clinical testing markets. Analysts at Jefferies highlighted the unit’s “unique position” in the sector, citing its 30% market share in point-of-care infectious disease tests.
For entertainment, the distinction matters. While molecular tests (like PCR) are more accurate, they require lab processing and are less practical for large crowds. Rapid antigen tests, which QuidelOrtho excels in, are faster and easier to deploy—critical for festivals and concerts where time is of the essence. A sale could therefore lead to a bifurcation in testing options, with some events opting for speed and others prioritizing precision.
What’s next for QuidelOrtho and the entertainment industry?
QuidelOrtho’s parent companies are expected to finalize their decision by the end of 2026, with a sale likely announced in early 2027. In the interim, event organizers should monitor the following:
Item
Announcements from Quidel Corporation and Thermo Fisher regarding strategic reviews.
Public filings detailing the testing unit’s financial performance and growth projections.
Competing bids from PE firms, which could influence the final valuation.
For the entertainment industry, proactive planning is key. Organizers may need to:
Item
Lock in testing contracts with alternative suppliers to avoid supply gaps.
Assess the financial impact of potential price increases from a new owner.
Explore partnerships with digital health firms that offer integrated testing and contact-tracing solutions.
The Financial Times reported that some PE firms are already approaching QuidelOrtho with non-binding offers, though no formal bids have been submitted. The process is likely to accelerate if Quidel’s stock continues to lag behind competitors like Abbott and Siemens Healthineers. For now, the testing unit remains operational, but the industry should brace for potential changes in 2027.
In the meantime, the entertainment sector’s dependence on diagnostics underscores a broader trend: the intertwining of healthcare and live experiences. As private equity reshapes the diagnostics landscape, event organizers will need to adapt—whether by diversifying suppliers, negotiating long-term contracts, or investing in alternative health-monitoring technologies. One thing is clear: the sale of QuidelOrtho’s testing unit is not just a healthcare story—it’s a potential turning point for how the world experiences live entertainment.